Panbela Therapeutics, Inc.
PBLA
$0.2603
-$0.0607-18.91%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.35M | 4.35M | 4.89M | 5.03M | 5.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.04M | 29.72M | 27.49M | 25.63M | 23.76M |
| Operating Income | -29.04M | -29.72M | -27.49M | -25.63M | -23.76M |
| Income Before Tax | -28.06M | -28.74M | -27.58M | -25.44M | -23.69M |
| Income Tax Expenses | -157.00K | -176.00K | -323.00K | -185.00K | -178.00K |
| Earnings from Continuing Operations | -27.91 | -28.56 | -27.26 | -25.25 | -23.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.91M | -28.56M | -27.26M | -25.25M | -23.51M |
| EBIT | -29.04M | -29.72M | -27.49M | -25.63M | -23.76M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -71.04 | -123.31 | -280.99 | -671.48 | -605.66 |
| Normalized Basic EPS | -20.50 | -54.96 | -155.92 | -399.95 | -382.84 |
| EPS Diluted | -71.04 | -123.31 | -280.99 | -671.48 | -605.66 |
| Normalized Diluted EPS | -20.50 | -54.96 | -155.92 | -399.95 | -382.84 |
| Average Basic Shares Outstanding | 13.07M | 8.36M | 3.55M | 432.60K | 195.40K |
| Average Diluted Shares Outstanding | 13.07M | 8.36M | 3.55M | 432.60K | 195.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |